Beyond this, the findings presented here highlight a path toward the development of innovative treatments for HF, with HDAC6 inhibition and subsequent myofibril stiffening potentially ameliorating cardiac diseases marked by excessive titin compliance and systolic dysfunction, and HDAC6 gain of function benefiting patients with DD that is associated with titin stiffening. The gene discussed is HDAC6; the disease is heart disorder.